Axel Schonthal | USC Profiles

Find more Research Resources

Axel Schonthal, PhD

Title	Associate Professor of Molecular Microbiology & Immunology
School	Keck School of Medicine of USC
Department	Molecular Microbiology and Immunology
Address	HMR 405A 2011 Zonal Avenue Health Sciences Campus Los Angeles California 90089
Phone	+1 323 442 1730
vCard	Download vCard

Overview

The Schonthal lab performs preclinical cancer research and pursues anticancer drug development. The main focus is on brain malignancies, which include primary brain cancers (such as glioblastoma) and secondary brain cancers (such as melanoma or breast cancer that has spread to the brain). The work is done in collaboration with Dr. Thomas Chen, Director of the USC Brain Tumor Group, and Dr. Florence Hofman from the Department of Pathology. This joint approach supports interdisciplinary efforts that translate laboratory findings to patient applications.

Biography

Education and Training

University of Karlsruhe, Germany	PhD		Molecular Biology
UC San Diego, San Diego, CA	Postdoc		Cancer Biology

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.

List All | Timeline

Chen TC, Yu J, Nouri Nigjeh E, Wang W, Myint PT, Zandi E, Hofman FM, Schönthal AH. A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells. Cancer Lett. 2017 Aug 01; 400:161-174. PMID: 28450161.

View in: PubMed
Chen TC, Da Fonseca CO, Schönthal AH. Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. Int J Mol Sci. 2016 Sep 02; 17(9). PMID: 27598140.

View in: PubMed
Chen TC, Cho HY, Wang W, Wetzel SJ, Singh A, Nguyen J, Hofman FM, Schönthal AH. Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. J Biomed Sci. 2015 Aug 19; 22:71. PMID: 26282951; PMCID: PMC4539921.

View in: PubMed, PubMed Central
Chen TC, Fonseca CO, Schönthal AH. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Am J Cancer Res. 2015; 5(5):1580-93. PMID: 26175929; PMCID: PMC4497427.

View in: PubMed, PubMed Central
Chen TC, Cho HY, Wang W, Nguyen J, Jhaveri N, Rosenstein-Sisson R, Hofman FM, Schönthal AH. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. Cancer Lett. 2015 Mar 28; 358(2):144-51. PMID: 25524552.

View in: PubMed
Chen TC, Cho HY, Wang W, Barath M, Sharma N, Hofman FM, Schönthal AH. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol Cancer Ther. 2014 May; 13(5):1181-93. PMID: 24623736.

View in: PubMed
Schönthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol. 2013 Mar 01; 85(5):653-66. PMID: 23000916.

View in: PubMed
Schönthal AH. Adverse effects of concentrated green tea extracts. Mol Nutr Food Res. 2011 Jun; 55(6):874-85. PMID: 21538851.

View in: PubMed
Schönthal AH. Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. Anticancer Agents Med Chem. 2010 Jul; 10(6):450-61. PMID: 20879982.

View in: PubMed